Avid Bioservices Inc (CDMO)

[chenzo11]

You are probably right. I didn't find the article all that flattering to be honest.

They was some positive:

shares rising from roughly $0.40 to above $5 following midstage data on bavituximab, its second-line drug for nonsmall cell lung cancer, or NSCLC.

Then some negative:

The ride wouldn't last long, though, with the stock crashing down by more than 80% after Peregrine noted, just weeks later, that the data shouldn't be trusted because of errors at a third-party clinical contractor.

Then some more positive:

Peregrine Pharmaceuticals had reported a statistically impressive 116% improvement in median overall survival to 12.1 months,

Then some more negative:

but its data was largely dismissed by investors who didn't know what to believe.

And then what could be construed as negative:

What's particularly unique, and the reason investors should pay close attention to Peregrine, is that bavituximab is one entrant into the extremely competitive race to develop cancer immunotherapies

Then some very positive:

If successful, bavituximab could revolutionize the second-line treatment for NSCLC, and it may hold promise as a first-line treatment, too.

Then some very negative:

Keep in mind, though, that small-cap biopharmas have a very poor track record of success when it comes to phase 3 oncology-based trials.

I'll call it a toss up. Yes, a lottery ticket

(I'll stick to the charts)

GLTA

Chenzo